Adjuvant Therapy for Renal Cell Carcinoma

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Daniel Shapiro, MD, FACS

CME Available:

https://cme.auanet.org/URL/RCCPOD261

ACKNOWLEDGEMENTS:

Support provided by an independent educational grant from:

Merck & Co., Inc.

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Define adjuvant therapy, review current clinical guidelines, and recognize the current landscape of treatment options for patients with RCC.

2. Compare and contrast different adjuvant therapies available for RCC, including targeted therapies and immunotherapies.

3. Identify common side effects associated with adjuvant therapies for RCC and provide strategies for managing and mitigating these adverse events in clinical practice.

4. Discuss ongoing clinical trials and new therapeutic targets under investigation for adjuvant treatment of RCC.